RBPJL and pancreatic neoplasm: The protein products from AGR2 [16, 23–25], CEAMAN6 [26–28], GNMT [29, 30], PDIA2 [31, 32], POSTN [17, 33, 34], RBPJL [35, 36] and S100P [37–39] have been reported as potential diagnostic and prognostic biomarkers for pancreatic cancer or have demonstrated to be involved in either pancreatic cancer, initiation, migration, invasion, metastasis, or chemoresistance.